Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report

It is of great clinical value to investigate the immune-related adverse events (irAEs), especially demyelinating lesions, caused by immune checkpoint inhibitors (ICIs). The incidence of demyelinating lesions is less frequent in irAEs, but once it occurs, it will seriously affect the survival of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenhui, Chen, Bo, Liu, Yiping, Luo, Zhiying, Sun, Bao, Ma, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762285/
https://www.ncbi.nlm.nih.gov/pubmed/35046822
http://dx.doi.org/10.3389/fphar.2021.799728
_version_ 1784633728198246400
author Liu, Wenhui
Chen, Bo
Liu, Yiping
Luo, Zhiying
Sun, Bao
Ma, Fang
author_facet Liu, Wenhui
Chen, Bo
Liu, Yiping
Luo, Zhiying
Sun, Bao
Ma, Fang
author_sort Liu, Wenhui
collection PubMed
description It is of great clinical value to investigate the immune-related adverse events (irAEs), especially demyelinating lesions, caused by immune checkpoint inhibitors (ICIs). The incidence of demyelinating lesions is less frequent in irAEs, but once it occurs, it will seriously affect the survival of patients. The present study reports a case of durvalumab-induced demyelinating lesions in a patient with extensive-stage small-cell lung cancer. Subsequently, the patient receives a high intravenous dose of methylprednisolone and his condition is improved after 21 days of treatment. Altogether, early diagnosis and treatment of ICIs-related neurological irAEs is of great significance to the outcome of the patient’s condition.
format Online
Article
Text
id pubmed-8762285
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87622852022-01-18 Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report Liu, Wenhui Chen, Bo Liu, Yiping Luo, Zhiying Sun, Bao Ma, Fang Front Pharmacol Pharmacology It is of great clinical value to investigate the immune-related adverse events (irAEs), especially demyelinating lesions, caused by immune checkpoint inhibitors (ICIs). The incidence of demyelinating lesions is less frequent in irAEs, but once it occurs, it will seriously affect the survival of patients. The present study reports a case of durvalumab-induced demyelinating lesions in a patient with extensive-stage small-cell lung cancer. Subsequently, the patient receives a high intravenous dose of methylprednisolone and his condition is improved after 21 days of treatment. Altogether, early diagnosis and treatment of ICIs-related neurological irAEs is of great significance to the outcome of the patient’s condition. Frontiers Media S.A. 2022-01-03 /pmc/articles/PMC8762285/ /pubmed/35046822 http://dx.doi.org/10.3389/fphar.2021.799728 Text en Copyright © 2022 Liu, Chen, Liu, Luo, Sun and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Wenhui
Chen, Bo
Liu, Yiping
Luo, Zhiying
Sun, Bao
Ma, Fang
Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
title Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_full Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_fullStr Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_full_unstemmed Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_short Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
title_sort durvalumab-induced demyelinating lesions in a patient with extensive-stage small-cell lung cancer: a case report
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762285/
https://www.ncbi.nlm.nih.gov/pubmed/35046822
http://dx.doi.org/10.3389/fphar.2021.799728
work_keys_str_mv AT liuwenhui durvalumabinduceddemyelinatinglesionsinapatientwithextensivestagesmallcelllungcanceracasereport
AT chenbo durvalumabinduceddemyelinatinglesionsinapatientwithextensivestagesmallcelllungcanceracasereport
AT liuyiping durvalumabinduceddemyelinatinglesionsinapatientwithextensivestagesmallcelllungcanceracasereport
AT luozhiying durvalumabinduceddemyelinatinglesionsinapatientwithextensivestagesmallcelllungcanceracasereport
AT sunbao durvalumabinduceddemyelinatinglesionsinapatientwithextensivestagesmallcelllungcanceracasereport
AT mafang durvalumabinduceddemyelinatinglesionsinapatientwithextensivestagesmallcelllungcanceracasereport

Ejemplares similares